1. Home
  2. DPRO vs PLX Comparison

DPRO vs PLX Comparison

Compare DPRO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Draganfly Inc.

DPRO

Draganfly Inc.

HOLD

Current Price

$7.92

Market Cap

230.7M

Sector

Industrials

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$3.00

Market Cap

230.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DPRO
PLX
Founded
1998
1993
Country
Canada
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
230.7M
230.0M
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
DPRO
PLX
Price
$7.92
$3.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$15.67
$12.00
AVG Volume (30 Days)
1.5M
1.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$53,399,000.00
Revenue This Year
$45.10
$9.67
Revenue Next Year
$149.99
$23.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.63
$1.34
52 Week High
$14.37
$3.19

Technical Indicators

Market Signals
Indicator
DPRO
PLX
Relative Strength Index (RSI) 49.65 73.68
Support Level $7.55 $1.39
Resistance Level $8.43 N/A
Average True Range (ATR) 0.67 0.16
MACD 0.08 0.01
Stochastic Oscillator 72.99 90.00

Price Performance

Historical Comparison
DPRO
PLX

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: